Clinical Trials Browser

Not yet recruiting × Triple Negative Breast Neoplasms × 30 days × Clear all

Recurrence, Triple Negative Breast Neoplasms

NCT07466303 2026-03-12

Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer

Phase 2 Not yet recruiting

84 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07458113 2026-03-09

BERLIN

Phase 2 Not yet recruiting

20 enrolled

BreastCNS

Brain Neoplasms, Triple Negative Breast Neoplasms

NCT07458204 2026-03-09

EPPIL

Phase 2 Not yet recruiting

760 enrolled

Breast

Recurrence, Triple Negative Breast Neoplasms

NCT07276880 2026-03-03

P-RAD(+)TN-DCT

Phase 2 Not yet recruiting

32 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07441512 2026-03-02

A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer Harboring a PIK3CA Mutation

Phase 2 Not yet recruiting

26 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07272642 2026-02-25

DUNP19

Phase 1 Not yet recruiting

16 enrolled

BreastGastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT07423117 2026-02-20

A Study of ITC-6146RO in Patients With Advanced or Metastatic Cancer Who Have Failed Standard Therapy

Phase 1 Not yet recruiting

102 enrolled

BreastThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT07419880 2026-02-19

RECLAIM

Phase 2 Not yet recruiting

46 enrolled

Breast

Triple Negative Breast Neoplasms

Clinical Trials

EINSTEIN-TNBC

Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer

BERLIN

EPPIL

P-RAD(+)TN-DCT

A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer Harboring a PIK3CA Mutation

DUNP19

A Study of ITC-6146RO in Patients With Advanced or Metastatic Cancer Who Have Failed Standard Therapy

RECLAIM